Alphavalue / Divacons | US fund Lone Star, which owns 75% of Novo Banco, formally received takeover offers from both Caixabank and French banking group BPCE. In addition to the buyout offers, Lone ...

Novo Nordisk said Hims & Hers has “failed to adhere to the law which prohibits mass sales of compounded drugs” and accused the telehealth company of “deceptive” marketing that is putting ...

On this news, Novo Nordisk’s stock price fell $4.05, or 5.5%, to close at $69.72 per share on June 23, 2025, thereby injuring investors. Contact Us To Participate or Learn More: ...

Novo Nordisk (NYSE:NVO) engages in the research & development, manufacture, and distribution of pharmaceutical products internationally. It has 2 segments: Diabetes & Obesity Care and Rare Disease.

The arrangement was short lived. On June 23, 2025, Novo Nordisk announced that it terminated the arrangement over its concerns about Hims & Hers' "illegal mass compounding and deceptive marketing." ...

In April 2025, Novo Nordisk and Hims & Hers Health announced a partnership to make the weight-loss drug Wegovy accessible through Hims' platform at £479 ($649) per month and less than two months ...

Novo Nordisk has terminated its short-lived collaboration with telehealth company Hims & Hers, a decision that led to a more than 30% drop in the U.S. firm's shares. The split occurred amidst conflict ...

Novo Nordisk confirmed on Monday it would cease its agreement with U.S. telehealth firm Hims & Hers Health regarding its Wegovy weight-loss drug, prompting a 31% dip in Hims shares during morning ...

When the collaboration between Novo Nordisk and Hims & Hers was announced in April, Wegovy was made available on Hims through Novo Nordisk’s NovoCare Pharmacy for a discounted price of $499 per ...